key: cord-0721656-ehm9su30 authors: Spencer, Elizabeth A; Klang, Eyal; Dolinger, Michael; Pittman, Nanci; Dubinsky, Marla C title: Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients date: 2021-08-24 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izab194 sha: b007080814cf4a27ce91cf289b5a01b2245c89be doc_id: 721656 cord_uid: ehm9su30 nan Protective immunity to SARS-CoV-2, either naturally induced by infection or artificially induced or augmented by vaccination, is vital to reducing the transmission of SARS-CoV-2 and the burden of severe coronavirus disease 2019 . Data on the impact of immunomodulatory therapies used to treat inflammatory bowel disease (IBD) on both types of protective immunity have been scant, with initial reports of attenuation of natural immunity and vaccine efficacy by TNF antagonists. 1,2 However, 2 doses of COVID-19 vaccine or a single dose in those with a history of SARS-CoV-2 infection have both been shown to induce seroconversion in a large majority of patients. 2, 3 There is little data on seroconversion in pediatric IBD, a population that may have distinct immunologic responses to SARS-CoV-2, given that increased age has been associated with lower antibody concentrations after COVID-19 vaccination. 2 Understanding seroconversion is particularly important as vaccination becomes more widely available in pediatrics with the recent emergency use approval of BNT162b2 (Pfizer-BioNTech) down to 12 years of age. 4 We therefore sought to evaluate and compare serologic responses to SARS-CoV-2 infection and vaccination in a pediatric IBD cohort. We conducted a retrospective chart review of all IBD patients younger than 21 years old in whom a SARS-CoV-2 immunoglobulin G (IgG) antibody assay was performed between April 2020 and May 2021 at our tertiary care center. The COVID-SeroKlir (Kantaro Biosciences, LLC, New York, NY) semiquantitative SARS-CoV-2 IgG antibody assay, an enzyme-linked immunosorbent assay (ELISA) measuring IgG antibody to the full-length SARS-CoV-2 spike protein with emergency use authorization, was routinely collected at infusion and outpatient clinic visits. 5 The study was approved by the Mount Sinai institutional review board. Electronic medical records were reviewed, and data were collected on demographics, IBD location and behavior (Paris classification), 6 exposure(s) to SARS-CoV-2, and history of SARS-CoV-2 infection/symptoms. Indication for antibody testing and titer levels, which were described as high titer or strongly positive (≥960 titer or >40 AU/mL), moderately positive (320-960 titer or 16-39 AU/mL), weakly positive (80-160 titer or 5-15 AU/mL), and negative 5 were recorded. Patients meeting World Health Ogranization (WHO) criteria for confirmed (laboratory confirmation of COVID-19 infection) or probable COVID-19 (either meeting defined clinical criteria with contact with a probable or confirmed case of COVID-19 or recent onset of anosmia/ageusia without an identified cause) were classified as having prior COVID-19 infection. 7 Standard descriptive statistics, including frequency for categorical variables and median (interquartile range [IQR]) for continuous variables, were calculated unless otherwise stated. Univariate analyses were performed using Fisher exact and χ 2 test for categorical variables and Mann-Whitney and Spearman Rank Coefficient for continuous variables where appropriate. Statistical analyses were performed using R 3.6.3 (The R Foundation for Statistical Computing, 2018) and SAS OnDemand for Academics 3.8 (SAS Institute Inc., Cary, NC, 2020). A P value ≤.05 was considered statistically significant. One or more SARS-CoV-2 IgG antibody assay(s) was performed in 340 pediatric patients; 15% (n = 51) were confirmed or probable for COVID-19; 2% (n = 7) were suspected for COVID-19; 16% (n = 54) were exposed to or had close contact with SARS-CoV-2 infection without clinical symptoms; 61% (n = 208) did not have any prior symptoms or exposures; and 6% (n = 20) had a history of COVI-19 vaccination. In the 51 patients with confirmed or probable COVID-19, 90% had seroconversion (Supplementary Table 1 ). Of the 5 patients without evidence of seroconversion, 3 had confirmed and 2 had probable COVID-19. Those that did not seroconvert were similar in age to the rest of the postinfection cohort (median 20 [17-20] years old, P = .15), with a trend to a higher proportion of patients with UC/ IBD-U (60%, P = .07); 4 patients (80%) were on a biologic therapy (3 infliximab, 1 ustekinumab), and the remaining patient was on 5-aminosalicylate (5-ASA). There was a significantly longer time interval between infection and titer level measurement in those with a negative titer (negative, 257 [167-340] days; positive, 112 [41-180] days; P = .03); however, titer level was not correlated with time from infection in the entire postinfection cohort (P = −0.06, P = .74). Within the 16% of patients with exposure to SARS-CoV-2 without clinical symptoms, 23 (43%) had a positive SARS-CoV-2 antibody assay. There were no identified clinical characteristics associated with seroconversion in the group exposed to SAR-CoV-2 without clinical symptoms (Supplementary Table 2) . Twenty patients had antibody testing after vaccination ( Table 1 ). All patients seroconverted following vaccination, and all patients receiving mRNA vaccination had high titer levels. The patient who received a single dose of JNJ-78436735 (Johnson & Johnson) had a moderate titer level. All but 1 (95%) of those receiving a 2-series mRNA vaccination had completed both vaccinations in the series; the single patient with an assay performed after only 1 dose of BNT162b2, with no prior history of SARS-CoV-2 infection, seroconverted. Titer level was not significantly associated with type of biologic or small molecule therapy ( Figure 1) ; patients receiving mRNA-1273 (NIH-Moderna) did have significantly higher titer levels compared to BNT162b2 and JNJ-78436735 (P = .005). Herein we report robust serologic antibody responses to SARS-CoV-2 infection and COVID-19 vaccination in a pediatric IBD cohort. All of our patients seroconverted after vaccination even in the setting of biologic and small molecule usage, which was similar to the findings in an adult IBD study published out of our center. 3 Moreover, nearly all (90%) of our patients had seroconversion following SARS-CoV-2 infection, which was higher than the rates seen in Kennedy et al, suggesting improved postinfection seroconversion in pediatrics. 1 The high titer levels achieved in a large number of those who seroconverted are thought to confer protection; however, the association with elapsed time from SARS-CoV-2 exposure to negative level warrants continued investigation into the longevity of the protection conferred and more detailed cataloging of the complexities of the immunoprotective response beyond IgG antibodies. Although we are limited by our small sample size and variable times to assay, this study provides important reassurances to pediatric gastroenterologists, patients, and families and lends further support to expert consensus recommendations for vaccination of IBD patients. 8 Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut: 2021 Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic A serological assay to detect SARS-CoV-2 seroconversion in humans Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification World Health Organization. Who COVID-19: Case Definitions. World Health Organization SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting The authors wish to thank the pediatric gastroenterologists at the Mount Sinai IBD Center and Randa Samaha, FNP.